Trial · NCT07900750
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to ART re-initiation (Stage 1) | From initial randomization through end of study follow-up, up to 12 months | Time to confirmed receipt of ART during a return clinic visit or community-based medication delivery by a navigator |
| Primary | Time to Repeat Treatment Interruption after Return (Stage 2) | From Return to Care and Second Stage Randomization to 12 months later | Time to missing a pharmacy refill by \>14 days after return |
| Primary | Proportion of Time Spent in Care and with medications (Stage 1 + Stage 2) | From Treatment Interruption until 18-months | Days spent in care and not \>14 days late for ART pick-up |
| Secondary | Viral Suppression | 12-18 months | Percentage of participants with documented viral suppression, defined as HIV RNA \<400 copies/mL, compared across the six embedded sequential return-and-reengagement strategies. Viral load data are drawn from the national electronic health record (SmartCare), supplemented by field-based viral load collection where necessary. |
| Secondary | Percentage of Participants Engaged in Care 12 to 18 Months After Initial Randomization | 12 to 18 months after initial treatment interruption | |
| Secondary | Time to return for a clinic visit | From initial treatment interruption through end of study follow-up, up to 12 months | Time from initial randomization to first completed HIV clinic visit |
| Secondary | Proportion who return to clinic within 3-months | At 3-months initial treatment interruption | |
| Secondary | Proportion successfully contacted via phone or in-person | At 3-months initial treatment interruption | |
| Secondary | Percent with at least one pharmacy refill missed by >30 days | From second-stage re-randomization up to 12 months | |
| Secondary | Percentage of Participants Attending Any Clinic Visit 6 to 12 Months After Return to Care | 6 to 12 months after return to care | |
| Secondary | Cost Effectiveness | 12 months | Assessing the cost-effectiveness of return strategies (Aim 1a), reengage strategies (Aim 1b), and sequential combination return-and-reengage strategies (Aim 2). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07900750/registered